tacrine has been researched along with Liver Dysfunction in 10 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Direct liver injury, possibly associated with the production of a toxic metabolite, would be consistent with reports of aberrant xenobiotic metabolism in Alzheimer's disease patients." | 2.67 | Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. ( Hardiman, S; Miller, K; Murphy, M, 1993) |
| "Tacrine is a cholinesterase inhibitor that increases the availability of acetylcholine in muscarinic neurons." | 2.39 | Tacrine: first drug approved for Alzheimer's disease. ( Crismon, ML, 1994) |
| "Tacrine is an acetylcholinesterase (AChE) inhibitor used as a cognitive enhancer in the treatment of Alzheimer's disease (AD)." | 1.38 | Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain. ( André, S; Domingues, MR; Francisco, CS; Maciel, E; Manuel Oliveira, M; Melo, T; Oliveira-Campos, AM; Peixoto, F; Rodrigues, LM; Videira, RA, 2012) |
| " The role of acute dosing rodent models in identifying candidate genes associated with drug-induced liver injury in man deserves further study." | 1.34 | Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. ( Alfirevic, A; Barratt, BJ; Carr, DF; Park, BK; Pirmohamed, M; Sherwood, J; Smith, J; Tugwood, JD, 2007) |
| " A reliable caregiver is essential to ensure compliance with frequent dosing and weekly blood testing." | 1.29 | Alzheimer's disease: how to give and monitor tacrine therapy. ( Lantz, MS; Woo, JK, 1995) |
| "Clinical trials with tacrine (THA) and its principal (1-OH) metabolite (velnacrine) for the treatment of Alzheimer's disease have been hampered by adverse hepatic events that were undetected in preclinical studies." | 1.29 | Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. ( Curren, RD; Viau, CJ; Wallace, K, 1993) |
| "Patients receiving THA for treatment of Alzheimer's disease need regular monitoring of liver function." | 1.28 | Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. ( Ames, DJ; Bhathal, PS; Davies, BM; Fraser, JR; Gibson, PR; Roberts, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (80.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Melo, T | 1 |
| Videira, RA | 1 |
| André, S | 1 |
| Maciel, E | 1 |
| Francisco, CS | 1 |
| Oliveira-Campos, AM | 1 |
| Rodrigues, LM | 1 |
| Domingues, MR | 1 |
| Peixoto, F | 1 |
| Manuel Oliveira, M | 1 |
| Carr, DF | 1 |
| Alfirevic, A | 1 |
| Tugwood, JD | 1 |
| Barratt, BJ | 1 |
| Sherwood, J | 1 |
| Smith, J | 1 |
| Pirmohamed, M | 2 |
| Park, BK | 2 |
| Woo, JK | 1 |
| Lantz, MS | 1 |
| Crismon, ML | 1 |
| Hardiman, S | 1 |
| Miller, K | 1 |
| Murphy, M | 1 |
| Watkins, PB | 1 |
| Zimmerman, HJ | 1 |
| Knapp, MJ | 1 |
| Gracon, SI | 1 |
| Lewis, KW | 1 |
| Viau, CJ | 1 |
| Curren, RD | 1 |
| Wallace, K | 1 |
| De Sousa, M | 1 |
| Kitteringham, NR | 1 |
| Woolf, T | 1 |
| Molloy, DW | 1 |
| Guyatt, GH | 1 |
| Wilson, DB | 1 |
| Duke, R | 1 |
| Rees, L | 1 |
| Singer, J | 1 |
| Ames, DJ | 1 |
| Bhathal, PS | 1 |
| Davies, BM | 1 |
| Fraser, JR | 1 |
| Gibson, PR | 1 |
| Roberts, S | 1 |
1 review available for tacrine and Liver Dysfunction
| Article | Year |
|---|---|
Tacrine: first drug approved for Alzheimer's disease.
Topics: Alanine Transaminase; Alzheimer Disease; Aspartate Aminotransferases; Chemical and Drug Induced Live | 1994 |
3 trials available for tacrine and Liver Dysfunction
| Article | Year |
|---|---|
Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
Topics: Age Factors; Aged; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibit | 1993 |
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
Topics: Aged; Alanine Transaminase; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Drug Administ | 1994 |
Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cogniti | 1991 |
6 other studies available for tacrine and Liver Dysfunction
| Article | Year |
|---|---|
Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain.
Topics: Adenosine Triphosphatases; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Choline | 2012 |
Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity.
Topics: Alanine Transaminase; Alzheimer Disease; Animals; Chemical and Drug Induced Liver Injury; Gene Expre | 2007 |
Alzheimer's disease: how to give and monitor tacrine therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alanine Transaminase; Alzheimer Disease; Chemic | 1995 |
Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Cells, Cultur | 1993 |
No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; DNA Primers; G | 1998 |
Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine.
Topics: Aged; Alzheimer Disease; Aminoacridines; Chemical and Drug Induced Liver Injury; Female; Humans; Liv | 1990 |